oncology

Sanofi defends top oncology drug with Jevtana patent win
Sanofi defends top oncology drug with Jevtana patent win
Fierce Pharma
Sanofi
patents
generics
Jevtana
oncology
Flag link:
AstraZeneca cancer drugs build as primary care shrinks
AstraZeneca cancer drugs build as primary care shrinks
Biopharma Dive
AstraZeneca
cancer
oncology
primary care
Tagrisso
Symbicort
Lynparza
Flag link:
Shifting focus to oncology, GSK recruits a cancer vet as new chief of US pharmaceuticals — adding another woman to the top ranks of biopharma
Shifting focus to oncology, GSK recruits a cancer vet as new chief of US pharmaceuticals — adding another woman to the top ranks of biopharma
Endpoints
GSK
oncology
Merck KGaA
Maya Martinez-Davis
Flag link:
Vesselon acquires FDA-approved Lipid Microsphere Drug Imagent for therapeutic platform
Vesselon acquires FDA-approved Lipid Microsphere Drug Imagent for therapeutic platform
Pharmaceutical Business Review
Vesselon
oncology
FDA
Imagent
liquid microspherePH
Flag link:
Lilly shuffles executives overseeing oncology and M&A
Lilly shuffles executives overseeing oncology and M&A
Biopharma Dive
Eli Lilly
oncology
M&A
Flag link:
Pfizer's keys to juggling 8 U.S. launches? Organization, accountability, clear goals
Pfizer's keys to juggling 8 U.S. launches? Organization, accountability, clear goals
Fierce Pharma
Pfizer
oncology
drug launches
biosimilars
Flag link:
Merck's Full Court Press On Oncology
Merck's Full Court Press On Oncology
Forbes
Merck
oncology
R&D
M&A
Tilos Therapeutics
Flag link:
Merck Bags Tilos, Adding an Immunotherapy Booster to Its Arsenal
Merck Bags Tilos, Adding an Immunotherapy Booster to Its Arsenal
Xconomy
Merck
M&A
Tilos Therapeutics
cancer immunotherapy
oncology
Flag link:
Servier, armed with Shire cancer drugs, builds out vision for U.S. future
Servier, armed with Shire cancer drugs, builds out vision for U.S. future
Fierce Pharma
Servier
oncology
Shire
M&A
Flag link:
ASCO 2019 preview: Big Pharmas looking for cancer R&D revival as we hit next-gen crossroads
ASCO 2019 preview: Big Pharmas looking for cancer R&D revival as we hit next-gen crossroads
Fierce Biotech
ASCO 2019
R&D
cancer
oncology
Flag link:
On the pulse of ASCO: pricing and clinical trial access
On the pulse of ASCO: pricing and clinical trial access
Pharmaforum
ASCO 2019
clinical trial access
clinical trials
oncology
drug pricing
Flag link:
FDA Approves First NDA Under Real-Time Oncology Review Pilot
FDA Approves First NDA Under Real-Time Oncology Review Pilot
RAPS.org
FDA
Novartis
oncology
Real Time Oncology Review
Piqray
Flag link:
Novartis sees Saudi Arabia as promising market for producing its cancer drugs
Novartis sees Saudi Arabia as promising market for producing its cancer drugs
Fierce Pharma
Novartis
oncology
cancer
Saudi Arabia
Flag link:
Amgen, Syapse enter precision medicine collaboration in oncology
Amgen, Syapse enter precision medicine collaboration in oncology
Pharmaceutical Business Review
Amgen
Syapse
precision medicine
oncology
cancer
Flag link:
Patient access pitfalls, regulatory inconsistencies hamper tissue agnostic drugs
Patient access pitfalls, regulatory inconsistencies hamper tissue agnostic drugs
BioCentury
FDA
ASCO
oncology
drug development
patients
clinical trials
tissue-agnostic drugs
Flag link:
Pfizer Inks Real-World Oncology Data Collaboration With Concerto HealthAI
Pfizer Inks Real-World Oncology Data Collaboration With Concerto HealthAI
BioSpace
Pfizer
Concerto HealthAI
oncology
real world data
real world evidence
Flag link:
Bristol-Myers Squibb and Concerto HealthAI Sign Cancer Real World Data Agreement
Bristol-Myers Squibb and Concerto HealthAI Sign Cancer Real World Data Agreement
BioSpace
Bristol-Myers Squibb
Concerto HealthAI
oncology
real world data
real world evidence
artificial intelligence
Flag link:
Early Stage Oncology Biotech Files for $100 Million IPO
Early Stage Oncology Biotech Files for $100 Million IPO
CP Wire
Turning Point Therapeutics
IPOs
oncology
Flag link:
Celgene taps Exscientia’s AI drug discovery tech for 3 new programs
Celgene taps Exscientia’s AI drug discovery tech for 3 new programs
Fierce Biotech
Celgene
Exscientia
artificial intelligence
oncology
autoimmune disease
drug discovery
Flag link:
Life Science Investment Grew 50% 2018 over 2017 -- New JD Supra Life Sciences Report
Life Science Investment Grew 50% 2018 over 2017 -- New JD Supra Life Sciences Report
CP Wire
JD Supra
investment
devices
biotech
IPOs
oncology
Flag link:

Pages